DEXTROSE INJ 5% BP (1000ML PC)

দেশ: মাল্যাশিয়া

ভাষা: ইংরেজি

সূত্র: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

সক্রিয় উপাদান:

DEXTROSE, ANHYDROUS/ANHYDROUS GLUCOSE

থেকে পাওয়া:

LUEN WAH MEDICAL CO. SDN. BHD.

INN (আন্তর্জাতিক নাম):

DEXTROSE, ANHYDROUS/ANHYDROUS GLUCOSE

প্যাকেজ ইউনিট:

1000ml mL

Manufactured by:

THAI OTSUKA PHARM CO LTD

তথ্য লিফলেট

Patient Information Leaflet
DEXTROSE INJECTION BP/USP
COMPOSITION:
Dextrose Injection B.P. contains 5g (5%), 10g (10%), 20g (20%), 25g
(25%), 30g (30%), 40g (40%) and
50g (50%) of Anhydrous Dextrose in each 100 ml.
Dextrose Injection U.S.P. contains 5g (5%), 10g (10%), 20g (20%), 25g
(25%), 30g (30%), 40g (40%) and
50g (50%) of Dextrose Monohydrate in each 100 ml.
THERAPEUTIC PROPERTIES:
Dextrose is used as a source of carbohydrate in parenteral nutrition
regimens. In the body, it is metabolized
to CO
2
and water with the release of energy.
INDICATIONS:
Dextrose Injection is indicated for water supply for dehydration,
drug-poison intoxication, circulatory
collapse, carbohydrate supply for hypoglycemia, hyperpotassemia,
cardiac disease (GIK therapy), supply of
water and calorie, solvent or diluent for other parenteral drugs.
ADVERSE EFFECTS:
Acute and large volume infusion: Since electrolyte may occur, careful
administration is required for acute
and large volume infusion.
CONTRAINDICATIONS:
Patients with hypotonic dehydration.
CAREFUL ADMINISTRATION:
1)
Patients with tendency of potassium deficiency
2)
Patients with diabetes
3)
Patients with urorrhagia
4)
Patients with renal failure
PRECAUTION IN USE:
1)
Since circulatory failure may occur due to a shift of electrolyte from
plasma by subcutaneous large
volume infusion, the solution should not be administered by
subcutaneous route.
2)
Hypertonic solution of Dextrose (500 ml products) must not be
administered from peripheral vein.
3)
Since thrombophlebitis may occur, careful administration is required
for the solutions (except for
5% solution).
4)
When a highly concentrated, hypertonic solution is infused, it is
desirable to administer starting
with a low concentration solution and gradually increase the
concentration.
5)
Sudden withdrawal of the infusion of a highly concentrated solution
may induce hypoglycemia.
6)
When used concomitantly with other drugs, due care should be taken for
physicochemical change
of the solution due to drug interaction.
7)
Glass ampoule

পণ্য বৈশিষ্ট্য

DEXTROSE INJECTION BP/USP
COMPOSITION:
Dextrose Injection B.P. contains 5g (5%), 10g (10%), 20g (20%), 25g
(25%), 30g (30%), 40g (40%) and
50g (50%) of Anhydrous Dextrose in each 100 ml.
Dextrose Injection U.S.P. contains 5g (5%), 10g (10%), 20g (20%), 25g
(25%), 30g (30%), 40g (40%) and
50g (50%) of Dextrose Monohydrate in each 100 ml.
THERAPEUTIC PROPERTIES:
Dextrose is used as a source of carbohydrate in parenteral nutrition
regimens. In the body, it is metabolized
to CO
2
and water with the release of energy.
INDICATIONS:
Dextrose Injection is indicated for water supply for dehydration,
drug-poison intoxication, circulatory
collapse, carbohydrate supply for hypoglycemia, hyperpotassemia,
cardiac disease (GIK therapy), supply of
water and calorie, solvent or diluent for other parenteral drugs.
ADVERSE EFFECTS:
Acute and large volume infusion: Since electrolyte may occur, careful
administration is required for acute
and large volume infusion.
CONTRAINDICATIONS:
Patients with hypotonic dehydration.
CAREFUL ADMINISTRATION:
1)
Patients with tendency of potassium deficiency
2)
Patients with diabetes
3)
Patients with urorrhagia
4)
Patients with renal failure
PRECAUTION IN USE:
1)
Since circulatory failure may occur due to a shift of electrolyte from
plasma by subcutaneous large
volume infusion, the solution should not be administered by
subcutaneous route.
2)
Hypertonic solution of Dextrose (500 ml products) must not be
administered from peripheral vein.
3)
Since thrombophlebitis may occur, careful administration is required
for the solutions (except for
5% solution).
4)
When a highly concentrated, hypertonic solution is infused, it is
desirable to administer starting
with a low concentration solution and gradually increase the
concentration.
5)
Sudden withdrawal of the infusion of a highly concentrated solution
may induce hypoglycemia.
6)
When used concomitantly with other drugs, due care should be taken for
physicochemical change
of the solution due to drug interaction.
7)
Glass ampoule product should be disinfect